Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Contrast-Induced Nephropathy Prevention

N-Acetylcysteine (Contrast Nephropathy)

Brand names: Parvolex (IV), effervescent tablets (oral)

N-acetylcysteine has been used, often orally, in attempts to prevent contrast-induced nephropathy in patients at risk undergoing contrast imaging, though its benefit is uncertain.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

Clinical monograph

How it works

It is a thiol-containing antioxidant and glutathione precursor proposed to reduce contrast-related oxidative stress and to have vasodilatory effects on the renal vasculature.

Prescribing in practice

  • Evidence for preventing contrast-induced nephropathy is weak and inconsistent, and it should not replace the mainstay of adequate intravenous hydration in at-risk patients.
  • It is generally well tolerated, with the oral route carrying few risks in this setting.
  • Hydration and minimising contrast volume remain the priorities in renal protection.

Monitoring

Monitor renal function (serum creatinine) around the time of contrast exposure in at-risk patients.

Counselling the patient

  • Staying well hydrated around the time of your scan is the most important protective step.
  • Take any prescribed preventive medication as directed before and after the procedure.
  • Report reduced urine output or swelling after the procedure.

Evidence & guidelines

Large trials such as PRESERVE found no benefit of N-acetylcysteine over placebo for preventing contrast-associated kidney injury, with hydration being the key measure.

Reference: PRESERVE Trial (Weisbord et al. NEJM 2018); NICE CKD Guidelines; SPC Parvolex; RCR Guidance on Contrast Media; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways